Tradestie Institutional Equity Comparison Engine

IMMX vs CDT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

IMMX Overall Edge

IMMX Captures Institutional Edge (3โ€“0 Pillars ยท 5โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immix Biopharma, Inc. Common Stock (IMMX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, IMMX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CDT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, IMMX sits in BREAKDOWN (30th %ile IV; Dealer Gamma Walls on Pro) against CDT sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
IMMX N/M vs CDT N/M Fwd P/E
Growth & Margin Winner IMMX
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner IMMX
1Y +64.5% vs -86.8% ยท 52W Pos 28% vs 2%
Options & Structure Winner IMMX
BREAKDOWN (30th %ile IV) vs BREAKDOWN (N/A IV)
IMMX NASDAQ
Immix Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$6.96
-1.14% 1D
Market Cap $590.0M
1M Return -16.65%
1Y Return +64.54%
Forward P/E N/M
Unified AI Score
50.6 / 100 HOLD
Tech 38.0 Fund 64.0 Flow 67.0 Mom 64.0
CDT NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap $507,528
1M Return +76.79%
1Y Return -86.78%
Forward P/E N/M
Unified AI Score
31.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IMMX +64.54% CDT -86.78% Spread: +151.32 pp (IMMX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
IMMX TTM Op. Margin: 0.0% CDT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMMX vs CDT. Trailing 12-month operating profitability (IMMX 0.0% vs CDT 0.0%) and valuation multiples (IMMX N/M vs CDT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IMMX (5) vs CDT (0)
Institutional Metric IMMX CDT Criterion Row Winner
Market Capitalization Scale $590.0M $507,528 Larger Scale IMMX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -27.0% -69.7% Higher ROE IMMX
52-Week Range Position Momentum 28% ($4โ€“$15) 2% ($0โ€“$11) Stronger Trend IMMX
Beta / 30D Volatility Risk Regime 1.65ฮฒ ยท 76% Vol -17.75ฮฒ ยท 10175% Vol Lower Realized Risk IMMX
Unified Institutional Score Composite Signal 50.6 / 100 (HOLD) 31.6 / 100 (SELL) Higher Composite IMMX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IMMX vs CDT Buy Guide
IMMX BREAKDOWN
62d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 30th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live IMMX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CDT BREAKDOWN
163d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CDT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IMMX nor CDT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.